Table 6 Confidence assessment in cumulative evidence using the GRADE framework
No. of studies | Certainty assessment | Effect | Certainty | Importance | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | No. of events | No. of individuals | Rate (95% CI) | |||
Composite outcome of > 50% decline in eGFR or ESRD (follow-up: median 2.5 years; assessed with the following: ml/min/1.73 m2) | |||||||||||
1 | Observational studies | Very serious | Not serious | Not serious | Serious | None | 288 | 2300 | ⨁◯◯◯ Very low | Important | |
End-stage renal disease (ESRD): < 15 ml/min/1.73 m2 (follow-up: median 2.5 years; assessed with the following: ml/min/1.73 m2) | |||||||||||
1 | Observational studies | Very serious | Not serious | Not serious | Serious | None | 214 | 2300 | ⨁◯◯◯ Very low | Critical | |